Category Medicine and Healthcare
Press Release
EX DEA Administrator Anne Milgram's "Swampy" Legacy: No-Bid Contracts, No Marijuana Reform, and No Accountability
MMJ BioPharma CEO Duane Boise summed it up bluntly: "Milgram's DEA was a monument to incompetence and indifference - and patients paid the price. Every day of delay meant another day people with Huntington's and Multiple Sclerosis went without hope. Terry Cole now has the chance to fix what she broke." Read More
Press Release
Peek Healthcare Technologies, Inc. ('Peek') Launches Direct-to-Employer and Direct-to-Patient Pricing for IMULDOSA(R) (ustekinumab-srlf) (Stelara(R) Biosimilar)
PeekDirect™ Delivers Transparent and Affordable Pricing for Brand and Specialty Drugs to Reduce Prescription Costs for Employers and Patients Read More
Press Release
NeoPredics Announces Market Launch of PreFree Across CE-Markets
- Clinical challenge: uncertainty in discharge and admission decisions for women at risk of preeclampsia - PreFree: the first CE-marked, multimodal prediction model for preeclampsia (biomarkers + clinical data) - Market launch in CE countries starting Q4 2025 Read More
Press Release
Rising Demand for Revision Rhinoplasty Leads Patients Worldwide to Dr. Shervin Naderi
The Naderi Center sees growing demand for revision rhinoplasty, with Dr. Shervin Naderi providing surgical and non-surgical solutions customized to patient needs, from advanced corrective surgery to filler-based nasal refinement. Read More
Press Release
Leaders Named in Accountable Care and Value-Based Care Technology and Advisory Ecosystem
Black Book Survey results reveal the twenty-five firms shaping the next generation of accountable care infrastructure released in orchestration with the opening events of the National Association of Accountable Care Organizations (NAACOS) Fall 2025 Meeting in Washington, D.C. Read More
Press Release
A DEA Bad Penny Keeps Turning Up: Ex-DEA Official Matthew Strait Resurfaces in the Online Pharmacy Lobby
The DEA Regulatory Revolving Door Spins Again After years of blocking FDA approved cannabis research for Huntington's and Multiple Sclerosis, former DEA official Matthew Strait has resurfaced on the board of ASOP Global, rebranding himself as a "patient safety" advocate. It's the ultimate Washington hypocrisy: the man who buried medical cannabis under red tape now lectures the world about access and safety. As MMJ CEO Duane Boise put it, "It's the regulatory equivalent of a bad penny that keeps turning up." Read More
Press Release
DEA Tribunal System Collapses: What MMJ BioPharma's Lawsuit Means for the Marijuana Rescheduling
Constitutional Earthquake: The End of the DEA's In-House Court DOJ's reversal on administrative law judge protections vindicates MMJ BioPharma's constitutional challenge and signals a seismic shift in DEA federal accountability. However, Public records discovered about DEA Attorney Aarathi Haig, from the State of New Jersey Board of Bar Examiners further complicate the picture. In an official letter dated February 14, 2023, the Board confirmed that while Ms. Haig "is not suspended from practice or disbarred," she was "not eligible to receive a Certificate of Good Standing" for several reasons. Read More
Press Release
2026 State of Release of Information Technology Report Reveals Market Consolidation, AI Integration, and Escalating Compliance Risks
New research from Black Book benchmarks U.S. healthcare's ROI technology landscape - complimentary report now available to providers and payers. Read More
Press Release
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose at Week 12 in the Phase 2b ANTHEM-UC study These data support the promise of a first-in-class targeted oral peptide that selectively blocks the IL-23 receptor as a potential new option for people with moderately to severely active ulcerative colitis Registrational Phase 3 study in ulcerative colitis and Phase 2b/3 study in Crohn's disease anticipated to begin patient enrollment in Q4 2025 Read More
Press Release
Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance
Findings show that Telomir-1 restores the body's natural tumor suppressor defenses by reversing abnormal DNA methylation of MASPIN and RASSF1A - genes that help block invasion, limit metastasis, and improve chemotherapy responsiveness in aggressive prostate cancer models. Read More
Press Release
ClearPoint Neuro Announces Expanded International Clearances for Key Therapy Delivery Product; Now Totaling 34 Countries Worldwide
The clearly established history across global regulatory bodies is expected to de-risk BioPharma partners' pathways towards achieving global scale and standardization. Read More
Press Release
DEA Marijuana Cruelty Disguised as Process: Will President Trump Stop Delay on Cannabis Medicine For Huntington's and MS Patients
For seven years, a critical application to grow cannabis for FDA approved medicine has languished at the Drug Enforcement Administration (DEA), sparking allegations that the agency is in "blatant violation of federal law" and blocking potential treatments for thousands of patients battling Huntington's Disease (HD) and Multiple Sclerosis (MS). Read More
Press Release
Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)
Additional update: Results of ongoing investigator-initiated proof-of-concept trial in United Arab Emirates (UAE) demonstrate further reduction of total parenteral support (PS) (comprised of total parenteral nutrition and supplementary IV fluids) of approximately 37% Read More
Press Release
Trump Marijuana Schedule I to Science: How MMJ International Holdings Is Defining the New Era of FDA Cannabis Medicine
"With DEA marijuana rescheduling and FDA oversight on the horizon, MMJ's pharmaceutical grade cannabinoid research stands as the model for a regulated, science driven future, stated Duane Boise CEO MMJ International Holdings. Read More
Press Release
Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025
Showcasing Disruptive Sublingual Drug Delivery Technology with Lead Program Targeting H2 2025 FDA Submission for Sublingual Aspirin Highlighting Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and a More-Rapid ED Medication Presentation and 1x1 Investor Meetings Scheduled Across the Two-Day Virtual Conference Read More
Press Release
Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne - - Dermata expects to launch a new once-weekly, Over-the-Counter (OTC) pharmaceutical acne kit, incorporating its Spongilla technology, in the middle of 2026 - - Over 3.3 million people are diagnosed with acne in Australia - Read More
Press Release